JP2015526391A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526391A5 JP2015526391A5 JP2015517382A JP2015517382A JP2015526391A5 JP 2015526391 A5 JP2015526391 A5 JP 2015526391A5 JP 2015517382 A JP2015517382 A JP 2015517382A JP 2015517382 A JP2015517382 A JP 2015517382A JP 2015526391 A5 JP2015526391 A5 JP 2015526391A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- fixed dose
- antibody
- agent according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659138P | 2012-06-13 | 2012-06-13 | |
| US61/659,138 | 2012-06-13 | ||
| PCT/US2013/045327 WO2013188494A1 (en) | 2012-06-13 | 2013-06-12 | Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231307A Division JP2018065845A (ja) | 2012-06-13 | 2017-12-01 | 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015526391A JP2015526391A (ja) | 2015-09-10 |
| JP2015526391A5 true JP2015526391A5 (https=) | 2016-07-14 |
Family
ID=49758685
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015517382A Pending JP2015526391A (ja) | 2012-06-13 | 2013-06-12 | 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン |
| JP2017231307A Pending JP2018065845A (ja) | 2012-06-13 | 2017-12-01 | 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン |
| JP2019033979A Active JP6814238B2 (ja) | 2012-06-13 | 2019-02-27 | 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン |
| JP2020174325A Ceased JP2021042208A (ja) | 2012-06-13 | 2020-10-16 | 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン |
| JP2021112707A Active JP7123225B2 (ja) | 2012-06-13 | 2021-07-07 | 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231307A Pending JP2018065845A (ja) | 2012-06-13 | 2017-12-01 | 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン |
| JP2019033979A Active JP6814238B2 (ja) | 2012-06-13 | 2019-02-27 | 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン |
| JP2020174325A Ceased JP2021042208A (ja) | 2012-06-13 | 2020-10-16 | 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン |
| JP2021112707A Active JP7123225B2 (ja) | 2012-06-13 | 2021-07-07 | 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9493570B2 (https=) |
| EP (1) | EP2861621A4 (https=) |
| JP (5) | JP2015526391A (https=) |
| KR (3) | KR102320059B1 (https=) |
| CN (3) | CN111494624A (https=) |
| AU (3) | AU2013274389A1 (https=) |
| CA (1) | CA2876636C (https=) |
| HK (1) | HK1209758A1 (https=) |
| WO (1) | WO2013188494A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035082T2 (en) * | 2004-06-21 | 2018-05-02 | Squibb & Sons Llc | Interferon alpha receptor 1 antibodies and their use |
| KR100680048B1 (ko) * | 2006-01-23 | 2007-02-08 | 쌍용자동차 주식회사 | 자동차 도장용 크레인의 구조 |
| EP3359690A4 (en) | 2015-10-09 | 2019-06-26 | Genefron Ltd. | METHODS AND KITS FOR PREDICTING AND DIAGNOSING CONGENITAL TRANSMISSION OF HUMAN CYTOMEGALOVIRUS (HCMV) |
| JP7308034B2 (ja) | 2016-07-01 | 2023-07-13 | リゾルブ セラピューティクス， エルエルシー | 最適化二重ヌクレアーゼ融合物および方法 |
| CN106243226B (zh) * | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| US20200031943A1 (en) | 2017-03-21 | 2020-01-30 | Austrianni Gmbh | Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases |
| BR112020003670A2 (pt) | 2017-08-22 | 2020-09-01 | Sanabio, Llc | receptores de interferon solúveis e usos dos mesmos |
| US11139051B2 (en) * | 2018-10-02 | 2021-10-05 | Origent Data Sciences, Inc. | Systems and methods for designing clinical trials |
| EA202191133A1 (ru) * | 2018-10-26 | 2021-07-12 | Янссен Байотек, Инк. | Сигнатуры интерферона типа i и способы их применения |
| JP7386877B2 (ja) * | 2019-01-31 | 2023-11-27 | イミューンセント バイオテクノロジー，インコーポレイテッド | 新規の抗ｉｆｎａｒ１抗体 |
| CN111892653A (zh) * | 2019-07-03 | 2020-11-06 | 长春恒晓生物科技有限责任公司 | 制备粘病毒抗性蛋白1抗体及建立检测mx1方法 |
| PT4192882T (pt) * | 2021-04-23 | 2025-05-02 | Astrazeneca Ab | Tratamento de nefrite lúpica com anticorpo anifrolumab de recetor inf anti-tipo i |
| HRP20231255T1 (hr) | 2021-04-23 | 2024-02-02 | Astrazeneca Ab | Režim doziranja anti-ifnar1 za potkožnu injekciju |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| GB202402824D0 (en) * | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002098370A2 (en) * | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
| US20040037809A1 (en) | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
| HUE035082T2 (en) * | 2004-06-21 | 2018-05-02 | Squibb & Sons Llc | Interferon alpha receptor 1 antibodies and their use |
| WO2006128210A1 (en) * | 2005-06-03 | 2006-12-07 | John Arthur Notaras | A tiller |
| EP1907858A4 (en) | 2005-06-13 | 2009-04-08 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| CA2651866C (en) | 2006-05-11 | 2014-10-28 | Universiteit Gent | Sialoadhesin-related compositions and methods |
| EP2077858A4 (en) | 2006-12-06 | 2011-07-20 | Medimmune Llc | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS |
| CN101594882A (zh) * | 2006-12-06 | 2009-12-02 | 米迪缪尼有限公司 | 干扰素α诱导的药代动力学标记物 |
| PT2219452E (pt) * | 2007-11-05 | 2016-01-26 | Medimmune Llc | Métodos de tratamento de esclerodermia |
| HRP20160855T1 (hr) * | 2008-02-08 | 2016-09-23 | Medimmune, Llc | Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda |
| US20110287022A1 (en) * | 2008-06-20 | 2011-11-24 | Medlmmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| UA104868C2 (uk) * | 2008-08-15 | 2014-03-25 | Меррімак Фармасьютікалз, Інк. | Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції |
| US20120251546A1 (en) | 2009-09-03 | 2012-10-04 | Medimmune Llc | Type 1 inteferon diagnostic |
-
2013
- 2013-06-12 AU AU2013274389A patent/AU2013274389A1/en not_active Abandoned
- 2013-06-12 KR KR1020207033413A patent/KR102320059B1/ko active Active
- 2013-06-12 EP EP13803921.9A patent/EP2861621A4/en not_active Withdrawn
- 2013-06-12 CN CN202010333445.7A patent/CN111494624A/zh active Pending
- 2013-06-12 HK HK15110286.5A patent/HK1209758A1/xx unknown
- 2013-06-12 KR KR1020147037151A patent/KR102185237B1/ko active Active
- 2013-06-12 US US14/407,156 patent/US9493570B2/en active Active
- 2013-06-12 CN CN201380043349.7A patent/CN104603152A/zh active Pending
- 2013-06-12 JP JP2015517382A patent/JP2015526391A/ja active Pending
- 2013-06-12 CN CN201810164604.8A patent/CN108310375A/zh active Pending
- 2013-06-12 CA CA2876636A patent/CA2876636C/en active Active
- 2013-06-12 WO PCT/US2013/045327 patent/WO2013188494A1/en not_active Ceased
- 2013-06-12 KR KR1020217034200A patent/KR20210130270A/ko not_active Ceased
-
2017
- 2017-12-01 JP JP2017231307A patent/JP2018065845A/ja active Pending
-
2018
- 2018-07-23 AU AU2018206851A patent/AU2018206851C1/en active Active
-
2019
- 2019-02-27 JP JP2019033979A patent/JP6814238B2/ja active Active
-
2020
- 2020-07-10 AU AU2020204613A patent/AU2020204613B2/en active Active
- 2020-10-16 JP JP2020174325A patent/JP2021042208A/ja not_active Ceased
-
2021
- 2021-07-07 JP JP2021112707A patent/JP7123225B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015526391A5 (https=) | ||
| JP2017048194A5 (https=) | ||
| CY1118442T1 (el) | Μεθοδοι αγωγης δια της χρησεως εκλεκτικων αναστολεων bcl-2 | |
| JP2014532649A5 (https=) | ||
| JP2013172734A5 (https=) | ||
| CY1120637T1 (el) | Πολυπεπτιδικα αντισωματα που ανταγωνιζονται cd40 | |
| RU2018132044A (ru) | Антитела против тау | |
| JP2011157378A5 (https=) | ||
| JP2016503793A5 (https=) | ||
| JP2012136541A5 (https=) | ||
| NZ606587A (en) | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof | |
| MX2018002631A (es) | Inhibidores de molecula pequeña de dyrkia y usos de los mismos. | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| JP2010534684A5 (https=) | ||
| JO3407B1 (ar) | مركبات رباعي هيدرو بيرازولو بيريميدين | |
| HRP20170468T1 (hr) | Bispecifična protutijela protiv baff i protiv il-17 | |
| JP2012092103A5 (https=) | ||
| WO2014205317A3 (en) | Cyclic peptides as protein targeting agents | |
| JP2015522045A5 (https=) | ||
| JP2011528896A5 (https=) | ||
| JP2013543499A5 (https=) | ||
| NZ773652A (en) | Β-d-2’-deoxy-2’-α-fluoro-2’-β-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment | |
| HK1220611A1 (zh) | 用於治疗胃肠道病症的组成物 | |
| JP2014028813A5 (https=) | ||
| JP2015513535A5 (https=) |